Mutations Can Persist After COVID-19 Monoclonal Antibody Treatment

The New England Journal of Medicine published a Correspondence from researchers in Australia on March 9, 2022, who reported that SARS-CoV-2 coronavirus might be isolated up to 24 days after sotrovimab treatment.

Sotrovimab is an innovative monoclonal antibody (mAbs) that is available under emergency authorizations to treat patients at risk for progression of COVID-19 to severe disease in the U.S. and various countries.

Sotrovimab is thought to neutralize all sarbecoviruses, including SARS-CoV-2, by binding to a highly conserved epitope within the receptor-binding domain.

However, using SARS-CoV-2–specific monoclonal antibodies to target a single viral epitope warrants caution because of the risk of rapid development of mutations that confer resistance after exposure to these antibodies.

The un-edited Correspondence - Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use - is posted on this weblink.

Other mAbs news is posted at PrecisionVaccinations.com/antibodies.